false 0001177648 0001177648 2021-02-05 2021-02-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 5, 2021

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

001-35839

04-3205099

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

 

(617) 607-0800

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17, CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

ENTA

 

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

 

Item 8.01 Other Events.

Enanta Pharmaceuticals, Inc. (the “Company”) previously entered into: (i) a Collaborative Development and License Agreement with Abbott Laboratories on November 27, 2006 (the “Original Agreement”), (ii) a First Amendment to Collaborative Development and License Agreement with Abbott Laboratories dated January 27, 2009 (the “First Amendment”) and (iii) a Second Amendment to Collaborative Development and License Agreement with Abbott Laboratories dated December 8, 2009 (the “Second Amendment”), all of which were assigned to AbbVie Inc. Subsequently, the Company entered into a Third Amendment to Collaborative Development and License Agreement with AbbVie Inc. dated October 20, 2014 (the “Third Amendment” and together with the Original Agreement, the First Amendment and the Second Amendment, the “AbbVie Agreement”).  The Securities and Exchange Commission previously granted confidential treatment for certain provisions of the AbbVie Agreement through February 5, 2021. In conjunction with the filing of this current report on Form 8-K, the Company is re-filing the AbbVie Agreement to comply with the requirements set forth in Item 601(b)(10)(iv) of Regulation S-K.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1†

Collaborative Development and License Agreement between the Company and Abbott Laboratories, dated November 27, 2006; as amended by a First Amendment to Collaborative Development and License Agreement dated January 27, 2009 and a Second Amendment to Collaborative Development and License Agreement dated December 9, 2009 (assigned to AbbVie Inc. as of January 1, 2013).

 

10.2†

 

Third Amendment to Collaborative Development and License Agreement between the Company and AbbVie Inc. dated October 20, 2014.

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

    

Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company has determined that such omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ENANTA PHARMACEUTICALS, INC.

 

 

 

 

Date: February 5, 2021

 

By:

/s/ Paul J. Mellett

 

 

 

Paul J. Mellett

 

 

 

Senior Vice President, Finance and Administration and Chief Financial Officer

 

2